Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

340B Patient Definition Gets Much-Needed Update In Omnibus Guidance

This article was originally published in The Pink Sheet Daily

Executive Summary

HRSA's long-awaited comprehensive guidance clarifies numerous program policies and procedures to help ensure integrity of the drug discount program.

You may also be interested in...



Senate 340B Draft Bill May Add Contract Pharmacy Limits, Has Placeholder For Patient Definition

A bipartisan group of senators issues a request for information to fill gaps in their wide-ranging draft bill on the 340B program. The legislation covers the participation of contract pharmacies, eligibility of "child sites," claims transparency, abuses by pharmacy benefit managers, and a third party claims clearinghouse that would monitor for duplicate discounts.

340B Freeze: 'Mega-Guidance' Withdrawn; Clarity On Program Boundaries Delayed Again

Long-delayed effort to define key boundaries for 340B drug discount program is on hold once again – and it may now take legislation to enable HRSA to move forward with plans to better define who is eligible for the discount.

340B “Mega-Guidance” Delayed To December (Or Beyond)

HRSA official stresses importance “good faith” by manufacturers and purchasers to assure program integrity while key definitions remain in limbo.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS078853

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel